All posts by imreal

Taiwan Food and Drug Administration Grants CTL Amedica Corp License to Market MATISSE™ ACIF Cage System


The MATISSE™ ACIF Cage System is available in numerous footprints, heights, lordotic angles and materials.

We’re honored by the TFDA’s approval and are excited to work with our Taiwan distributor partner to make this important spinal technology readily available throughout Taiwan.

The Taiwan Food and Drug Administration (TFDA), a part of the Ministry of Health and Welfare, has granted CTL Amedica Corporation a license for the MATISSE™ Anterior Cervical Interbody Fusion (ACIF) Cage System. The official license, DHA 05603556709, enables CTL Amedica to market the MATISSE™ ACIF Cage System in Taiwan, a crucial medical device market, particularly for spinal technology.

“We’re honored by the TFDA’s approval and are excited to work with our Taiwan distributor partner to make this important spinal technology readily available throughout Taiwan,” said Daniel Chon, CEO of CTL Amedica. “We hope to have it commercially available throughout Taiwan in the coming months and eventually in markets throughout Asia.”

Named after the famous French impressionist painter Henri Matisse, the MATISSE™ ACIF Cage System is a work of art and of science, engineered to accommodate a wide range of patient anatomies and surgeon preferences. It features streamlined instrumentation and a tapered leading edge for easy insertion, as well as, a large graft area to further promote bone fusion.

The MATISSE™ ACIF Cage System is available in numerous footprints, heights, lordotic angles and materials, including Titanium, PEEK and Titanium-plated PEEK. Both Titanium and Titanium-plated PEEK feature CTL Amedica’s proprietary TiCro™ surface technology. TiCro™ surface technology significantly increases contact surface area and enhances bone interlocking properties.

CTL Amedica is a forward-thinking medical device design, development and manufacturing company. CTL Amedica maintains a Texas-based headquarters and in-house manufacturing facility, along with a Pennsylvania-based R&D Center of Excellence. A leader in the medical device technology and biomaterials space, CTL Amedica provides a full line of cervical, thoracic and lumbar fusion and fixation products. In addition, it is the world’s exclusive provider of silicon nitride spine products. Silicon nitride demonstrates an enhanced osteogenic response for enhanced fusion, promotes unique anti-bacterial properties and provides comprehensive imaging across all modalities. For more information, visit https://www.ctlamedica.com/.

Share article on social media or email:

Results from the PPMI Study on an Alpha-Synuclein Seed Amplification Assay


International Congress of Parkinson’s Disease and Movement Disorders ®

International Congress of Parkinson’s Disease and Movement Disorders ®

“Recent advances in biochemical and imaging markers are opening novel perspectives for improving both the diagnosis, the definition, and the treatment of Parkinson’s disease. In this context, the PPMI study emerges as a global effort that holds great promise for a wide range of analyses.”

An alpha-synuclein seed amplification assay (SAA) showed positive detection results in prodromal cases of Parkinson’s disease according to a study released today at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

Development of tests to detect biomarkers for Parkinson’s disease (PD) are highly sought after to help with clinical care for potential PD patients. Biomarkers, such as alpha-synuclein, can aid in early diagnosis and risk assessment for PD development.

The Parkinson Progression Marker Initiative (PPMI) is a large observational study consisting of phenotyped PD patients, individuals at risk for developing PD, and healthy controls. Siderowf et al. sought to evaluate the efficiency of an alpha-synuclein SAA (developed by Amprion) on cerebral spinal fluid (CSF) samples from these groups of individuals. A total of 1,139 participants were included in this study. Sensitivity and specificity of the SAA was assessed and showed the highest accuracy in typical PD patients but was still found to show positive results in majority of prodromal cases.

Tiago Outeiro, Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen, responded to this study, “recent advances in biochemical and imaging markers are opening novel perspectives for improving both the diagnosis, the definition, and the treatment of Parkinson’s disease. In this context, the PPMI study emerges as a global effort that holds great promise for a wide range of analyses. Using CSF samples from 1,139 cases, this research consortium assessed the value of an alpha-synuclein seed amplification assay (SAA) in a large cohort of patients with PD, individuals at-risk for PD and healthy controls. This is the major strength of this study, as previous efforts used a much smaller number of samples. The study confirmed the sensitivity and specificity of the SAA assay, as well as the ability to detect alpha-synuclein amplification in the CSF prodromal cases. Importantly, the study indicates that SAA will be an important tool to aid in the establishment of cohorts suitable for observational and interventional studies.”

View the full abstract text:

https://movementdisorders.org/2022-Congress-LBAs

Reference #: LBA-7

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

VPL is Heading to Orlando to Present at the NASP 2022 Annual Meeting & Expo


VPL TrajectRx

VPL presenting at specialty pharmacy’s premier event

“This event will really help us show the industry what we can do to help pharmacies simplify their prescription shipping workflows.”

This year’s National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo celebrates the 10-year anniversary of specialty pharmacy’s premier event, and VPL, an industry leader in smart supply chain solutions for healthcare clients, is continuing to support their expansion into the pharmacy market by exhibiting their cloud-based pharmacy solutions at the event. NASP 2022 will take place in Orlando, Florida at the Gaylord Palms Resort & Convention Center from September 19-22.

This past March, VPL announced the launch of their specialty pharmacy software solutions, VPL TrajectRx™—a clinically minded prescription shipping, tracking and compliance software built for pharmacists, by pharmacists to ensure specialty medications are delivered cost-effectively and securely.

“We’re excited to bring our pharmacy solutions to this year’s NASP Annual Meeting & Expo for the first time ever,” says Eric McGlade, CEO and Co-Founder at VPL. “Amanda Awe, our Pharmacy Product Specialist, spent over 10 years as a clinical pharmacist before coming to VPL to help other pharmacists solve familiar problems with technology solutions. Her unique perspective helps us to continuously innovate VPL TrajectRx, making it as useful to our customers as it can possibly be.”

VPL is proud to be leading two presentations for the Technology Day Workshop on Monday, September 19 in the mezzanine coastal breakout room Suwannee 1.

The first session, titled “Innovation Lab #5 – VPL & St. Luke’s,” is from 12:00-12:30 p.m. and will be presented by Marc Choquette (St. Luke’s), Derrek Seif (VPL), and Amanda Awe, PharmD, RPh (VPL). In this presentation, VPL will present a case study with a pharmacy customer that will demonstrate real world results of VPL TrajectRx.

The second session, titled “The Role of Technology in Solving ‘The Last Mile’ Logistics,” is from 4:30-5:30 p.m. and will be presented by Sheila Arquette, RPh (NASP), Amanda Awe, PharmD (VPL), Tim Ramsey (US Pack Logistics), Kirk Nilson (Parcel Shield). This panel will describe how specialty pharmacies use technology to provide customized, convenient, and customer-centric last-mile solutions to accommodate patients’ needs, improve customer satisfaction, manage costs, and safeguard medication quality.

“This event will really help us show the industry what we can do to help pharmacies simplify their prescription shipping workflows.” says McGlade. “I think those who sit in on her presentations will really enjoy them because they’ll be getting perspective on pharmacy software from an actual pharmacist who played a big role in the development of it all.”

Attendees can stop by the VPL TrajectRx booth (#606) to chat with their team about specialty pharmacies can make the prescription shipping workflow more seamless than ever before, find out what giveaway prizes they have available, and see what tricks their booth-side magician has up his sleeves.

About VPL

By making the procurement-through-fulfillment processes smarter and more profitable, VPL is creating a new supplier dynamic whereby customers benefit from reduced costs, better insights, and increased transparency and efficiency. The industry’s only Smart Supply Chain Platform automates inbound and outbound shipping, unlocks visibility into the status of critical shipments, and identifies cost-savings opportunities for all of healthcare including IDNs, critical access, outpatient, and pharmacy. With more than 700 hospitals pharmacies, and ambulatory surgery centers, 6,000+ suppliers, and a 97% customer retention rate, it’s clear that VPL is the company the healthcare industry trusts to deliver savings, insights, and peace of mind. To learn more or to schedule a demo, visit the company’s website at http://www.getvpl.com.

About NASP

NASP is a 501(c)(6) non-profit trade organization and is the only national association representing all stakeholders in the specialty pharmacy industry. The mission of the National Association of Specialty Pharmacy (NASP) is to elevate the practice of specialty pharmacy by developing, delivering, and promoting continuing professional education and specialty certification while advocating for public policies that ensure patients have appropriate access to specialty medications in tandem with critical services. NASP supports a free-market healthcare system in which all specialty pharmacies compete on the same fair and level playing field, because that is in the best interest of the patients we collectively serve. NASP is committed to working with all stakeholders and policymakers to ensure that all patients have access to the life-saving medications they need and the high touch patient care and support services they deserve from the pharmacy of their choosing. To learn more, visit http://www.naspnet.org.

Share article on social media or email:

DeliverHealth’s Digital Health Platform Ranks No. 1 for Improving Patient Experience in KLAS 2022 Emerging Solutions Top 20 Report


News Image

We’re proud to be recognized by KLAS as being on the forefront of digital health software and services and giving patients the tools they’ve been asking for while demonstrating the positive impact on clinicians, as our industry forges a new path toward digital-first care delivery models.

DeliverHealth, a software and services company with a set of connected solutions that bridge the gap between mid-revenue cycle and digital health, announced today that its digital health platform has received high rankings in the 2022 KLAS Emerging Solutions Top 20 Report, including the top ranking in KLAS’s Improve Patient Experience category.

Built on its award-winning digital front door software and wrapped with a suite of omni-channel communication tools ranging from AI Virtual Assistant to Live Agent, the solution creates a one-of-a-kind user experience to enable Electronic Medical Record (EMR) functionality, scheduling, payment, telehealth visits, health risk assessments, patient monitoring, wayfinding, and more, in a single white-labeled, client-branded mobile application and web experience workflow.

The top 20 emerging solutions were selected by healthcare leaders across the country with the help of KLAS to find the solutions that have the greatest potential to disrupt the healthcare market. Solutions were rated by how well they could improve outcomes, reduce the cost of care, improve patient experiences, and improve clinician experiences, also known as the Quadruple Aim.

Notably, of the solutions considered by KLAS in relation to the Quadruple Aim, DeliverHealth ranked as the No. 1 solution for Improving Patient Experience, No. 4 for Improving Clinician Experience, tied at No. 6 for Improving Outcomes and tied at No. 9 for Reducing the Cost of Care — a testament to the company’s vision of simplifying the complexities in healthcare.

According to the report, one C-level executive noted being “very impressed” by DeliverHealth’s patient experience software, as “it wrapped functionality from several disparate solutions quite nicely, creating a seamless consumer experience.”

CEO of DeliverHealth Michael Clark said, “With 63% of patients now willing to leave their existing provider for one with a better digital experience, health systems have struggled to develop and execute holistic digital health strategies that unify the hundreds of available point solutions into a seamless consumer experience. DeliverHealth’s solutions integrator approach allows our clients to do just that, while our team of digital health consultants make sure our client’s people and processes are set up to drive adoption of their newly unified technologies. We’re proud to be recognized by KLAS as being on the forefront of digital health software and services and giving patients the tools they’ve been asking for while demonstrating the positive impact on clinicians, as our industry forges a new path toward digital-first care delivery models.”

The DeliverHealth Platform, with its mobile-focused capabilities, puts a clinical documentation and a coding ecosystem in the palms of a clinicians’ hands, providing quick access to transcription, scribing, translation services, coding audit workflows, and more. As the industry’s first true Digital Health Solutions Integrator, DeliverHealth incorporates into its digital front door omni-channel capabilities more than 30 point solutions and offers a team of adoption specialists to help customers create the healthcare ecosystem of the future, today. Earlier this year, those digital front door capabilities earned across-the-board A+ ratings from KLAS.

In KLAS’s Emerging Solutions Top 20 Report, another C-level executive mentioned that “any product [like DeliverHealth’s] that can bring together all the resources patients need into one platform is attractive to healthcare organizations trying to maintain a competitive edge.”

“Because KLAS believes in the power of technology to improve healthcare, it only made sense to research emerging, new solutions,” said Adam Gale, KLAS CEO. “We set out to help providers cut through the hype in this market and we found some new technologies with real capabilities. The recent Top 20 report highlights those solutions with the greatest potential impact according to healthcare leaders.”

To learn more about how DeliverHealth can help improve patient engagement and experience, visit http://www.deliverhealth.com.

About DeliverHealth

DeliverHealth is a healthcare software and services company with a set of connected solutions that bridge mid-revenue cycle and digital health together to improve the capabilities of health organizations to increase revenue, lower costs, demonstrate a return on investment, and create a healthier patient base. By building simplicity into our documentation, codification, and digital health patient experience platform, we make sure your people, processes, technology and patients are aligned and engaged for better outcomes and greater success. With clients and operations in five countries, and over three decades of Health Information Management expertise, DeliverHealth empowers today’s providers for the future of healthcare. Visit http://www.deliverhealth.com, or find us on LinkedIn, Twitter and Facebook.

About KLAS

KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights that provide early insights on the future of healthcare technology solutions. Follow KLAS on LinkedIn. Learn more at: klasresearch.com.

Share article on social media or email:



SightMD Welcomes R. Scott Russell, MD to Their Expert Team


News Image

When asked why he chose the SightMD team, Dr. Russell said “The physicians and staff at SightMD are a team of dedicated, caring and compassionate experts placing the well being and needs of the individual above all else – which is consistent with my own philosophy and goals of patient care.”

SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Scott Russell, MD to its expert team.

R. Scott Russell, MD is a comprehensive ophthalmologist who takes a genuine interest in researching and educating himself on various new advancements in ophthalmology, so his patients get the best and the most advanced treatment possible. He is driven to provide an excellent healthcare experience to all of his patients. Dr. Russell completed his undergraduate education at Boston College and Harvard College graduating with honors. He was awarded an N.I.H. Neurobiology Training Grant to study at the College of Physicians and Surgeons of Columbia University. After medical school he completed a general surgical internship at New York University, and his ophthalmology residency at Cornell. He also completed fellowships in Ophthalmic Pathology at the Armed Forces Institute of Pathology, and in Corneal, External Disease and Refractive Surgery at the L.S.U Eye Center. Dr. Russell served as a full time staff member in the Department of Ophthalmology of Columbia University and is an Assistant Clinical Professor in the department. His research interests include corneal pathology, and anterior segment surgery, about which he has published several papers and delivered several presentations. Dr. Russell will be seeing patients at SightMD locations in Riverhead (54 Commerce Dr Ste 6, Riverhead, NY 11901), Southold (41705 County Road 48, Southold, NY 11971), and Southampton (186 Old Town Road, Southampton, NY 11968).

When asked why he chose the SightMD team, Dr. Russell said “The physicians and staff at SightMD are a team of dedicated, caring and compassionate experts placing the well being and needs of the individual above all else – which is consistent with my own philosophy and goals of patient care.”

SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact our VP of Growth, Franc Galinanes, at (631) 396-8340 or fgalinanes@sightgrowthpartners.com

About SightMD

SightMD is a rapidly-growing integrated ophthalmic provider group, offering patients access to over 80 eye care providers through the convenience of 40 locations across New York. SightMD’s track record of providing clinically-excellent care spans over 50 years, and its services include general eye exams, laser cataract surgery and lens implantation, glaucoma management, retinal disorder treatment, corneal services, neuro-ophthalmology, LASIK laser vision correction, oculoplastic surgery, pediatric ophthalmology, and audiology. Sight Growth Partners is the administrative services provider for SightMD. For more information about SightMD, please visit https://www.sightmd.com/sightmd-ny/

Share article on social media or email:

Results from a Phase III Clinical Trial for Subcutaneous Infusion of Foslevodopa/Foscarbidopa


International Congress of Parkinson’s Disease and Movement Disorders ®

International Congress of Parkinson’s Disease and Movement Disorders ®

“This study is an important milestone in the development of continuous drug-delivery strategies to treat motor fluctuations in PD, showing significant increases in ON-time without troublesome dyskinesias using subcutaneous 24-hour infusions of a novel levodopa/carbidopa formulation.”

Continuous subcutaneous infusion (CSCI) of levodopa/carbidopa prodrugs, foslevodopa/foscarbidopa, improved time without dyskinesia in patients with advanced Parkinson’s disease (PD) according to a phase 3 clinical trial released today at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

It is well known that long-term use of oral levodopa/carbidopa leads to increased dyskinesia in PD patients. These motor symptoms are thought to be due to the rise and fall of dopamine. Therefore, many investigations have taken place to help treat and prevent the development of levodopa-induced dyskinesia.

The phase 3 clinical trial designed by Soileau et al. investigated the efficiency and safety of 24-hour CSCI foslevodopa/foscarbidopa, in patients with advanced PD. One hundred forty-one patients were randomized 1:1 to receive CSCI of foslevodopa/foscarbidopa and an oral placebo or CSCI of placebo and an oral dose of levodopa/carbidopa for 12 weeks. Treatment with CSCI of foslevodopa/foscarbidopa produced a greater improvement in time without dyskinesia when measured at week 12.

Werner Poewe, Professor of Neurology at the Medical University Innsbruck, Austria, responded to this study, “This study is an important milestone in the development of continuous drug-delivery strategies to treat motor fluctuations in PD showing significant increases in ON-time without troublesome dyskinesias using subcutaneous 24-hour infusions of a novel levodopa/carbidopa formulation. The observed effect size is similar to previous studies of levodopa/carbidopa intestinal gel infusions and results on secondary outcomes suggest benefits on sleep and early morning motor function. Local tolerability appears consistent with what is known from continuous subcutaneous apomorphine infusions in PD, suggesting that subcutaneous infusions of levodopa will soon be added to the portfolio of treatment options in PD patients with levodopa-related motor complications.”

View the full-text abstract:

http://www.mdsabstracts.org

Reference #: 775

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

PetMeds® to Participate in Jefferies’ Pet Care and Wellness Conference


PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert®, announces its participation in Jefferies’ Pet Care and Wellness Conference, a virtual event scheduled for Sept. 22.

PetMed Express CEO and President Matt Hulett and CFO Christine Chambers will represent the company at the conference, speaking with institutional investors and others in the financial community.

PetMeds® will join other leading pet care and wellness companies at the virtual event hosted by Jefferies. For more information on the conference, click here: https://www.jefferies.com/IdeasAndPerspectives/ConferenceList/Investment-Conferences/159

###

ABOUT PETMEDS

Founded in 1996, Petmeds.com is Your Trusted Pet Health Expert, providing fast, easy and helpful service to over 10 million customers across North America. PetMeds delivers prescription and non-prescription medications and pet supplies for less, direct to the consumer through its PetMeds® toll-free number, on the Internet through its website Petmeds.com, or with the PetMeds® free mobile app available for Apple and Android devices.

FORWARD LOOKING STATEMENTS: The statements contained in this press release that are not purely historical are forward-looking statements, including statements regarding PetMeds’ expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this press release are based upon information available to PetMeds as of the date hereof, and PetMeds assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. These and other risks relating to PetMeds’ business are set forth in PetMeds’ Form 10-K for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission.

INVESTOR RELATIONS CONTACT

investor@1800petmeds.com

MEDIA CONTACT

Mary Eva Tredway

Butin PR

maryeva@butinpr.com

Share article on social media or email:

Family Source Consultants Celebrates 15 Years of International Surrogacy


Two fathers with their daughter

FSC has helped hundreds of international intended parents realize their dreams.

“We take great pride in providing the communication, guidance, and support our prospective parents need to feel comfortable and well informed at each step of their surrogacy journey.”

The Chicago-based surrogacy agency opened its doors 15 years ago, initially working with domestic clients and a handful of Intended Parents (IPs) in Spain. Now, its client base spans some 34 countries, including much of Europe and Asia and as far afield as Australia.

In the past five years alone, FSC has helped over 200 international IPs realize their dreams.

And, with many expectant parents located in new countries, that client base will continue to grow. Even the pandemic has barely slowed demand.

FSC is now eagerly looking forward to greeting more new IPs at the 2022 Men Having Babies Conference & Expo in Brussels on September 16. The Parenting Options for European Gay Men conference is an opportunity for gay dads and dads-to-be to interact with one another and meet surrogacy providers and other experts.

FSC International Relations Manager Jessica Williams says meeting dads in person will be exciting for both parties.

“We get to meet Intended Parents at all stages of their journeys and provide information and support to help them make informed choices. It’s wonderful to be able to play this part in their lives,” she shared.

FSC owner and CEO Staci Swiderski says that surrogacy in the US is sometimes the only option for international parents.

“Many countries either prohibit or make it very difficult for Intended Parents to enter into surrogacy arrangements, which makes the US very attractive for pursuing surrogacy.”

More importantly, she adds, the US is home to experienced surrogacy agencies and reproductive attorneys, as well as fertility clinics with high success rates.

“Surrogacy in the US is safe, ethical, and reliable,” Swiderski says. “The stability and predictability are unmatched.”

Arranging a pregnancy with a US surrogate while living in another country may seem harrowing, but this is where FSC shines. Swiderski says their international clients receive the utmost care and attention from day one.

“We understand that for Intended Parents who live outside of the United States, building a family via surrogacy requires a great deal of diligence,” she says. “We take great pride in providing the communication, guidance, and support our prospective parents need to feel comfortable and well informed at each step of their surrogacy journey.”

FSC’s international program caters to all parents regardless of their geographic location, cultural background, or language. Their staff includes speakers fluent in Spanish, French, German, Mandarin, and Japanese. Translators are sourced when necessary, ensuring all clients can communicate in their preferred language. Client Relations Managers in France and China are also available to IPs in Europe and Asia.

Williams is based in the UK and works closely with other parents-to-be. As a former IP herself, she has a personal understanding of the emotional journey that surrogacy involves.

“We know from experience that there is an extra level of care and support that’s often needed with international surrogacy journeys,” she says. “From the first moment IPs reach out to FSC, we ensure they have any referrals to other professionals, such as local attorneys or fertility clinics. We want them to know that FSC will look after them and that their parental rights will be protected.”

With connections to attorneys, clinics, and other professionals both in the US and abroad, FSC can quickly provide IPs with the assistance they need. The team also facilitates other aspects of the journey, such as booking flights, accommodation, and other travel. The support continues after the baby’s birth, with help in sourcing baby equipment and obtaining any documentation or legal work.

“Whether it’s a referral to a legal expert in their home country or a clinic to provide sperm abroad before shipping it to the US, we’ll be there to help,” says Williams. “None of our IPs are simply numbers to us – they all become part of the FSC Family and are treated as such.”

Williams will be attending the Parenting Options for European Gay Men conference with fellow Client Relations Manager Jérôme Brun – another former IP – who is based in France.

“Both Jérôme and I understand how daunting this process can seem at the beginning. We hope that our collective experience can provide support and guidance to other Intended Parents,” she says.

Share article on social media or email:

Intelerad Acquires Life Image, Establishing the Clear Medical Image Exchange Market Leader and Path to a Global Open Image Exchange Network


News Image

Bringing together two of the industry’s leading image exchange providers further solidifies Intelerad’s commitment to helping clinicians and patients lead the revolution in imaging from a world of siloed PACS to a future of interoperable image exchange.

Today, Intelerad Medical Systems™, a leading global provider of enterprise imaging solutions, announced its acquisition of Life Image, one of the largest image exchange networks of curated clinical and imaging data, creating the largest medical image exchange network in the world and laying the groundwork for the elimination of costly CDs as the primary means of image transfer.

“As a company, Intelerad has been unwavering in backing the challenge put forth by the American College of Radiology (ACR), RSNA and SIIM to #ditchthedisk. Today’s transaction reflects one of the most important steps we could imagine in reaching that vision,” said Mike Lipps, Intelerad CEO. “Bringing together two of the industry’s leading image exchange providers further solidifies Intelerad’s commitment to helping clinicians and patients lead the revolution in imaging from a world of siloed PACS to a future of interoperable image exchange.”

Medical record interoperability has been a key component of the 21st Century Cures Act and its focus on eliminating all forms of information blocking. Radiology leaders and industry stakeholders have been champions for establishing a framework for seamless electronic image transfer in an effort to improve patient care and eliminate the burden on caregivers. By combining two of the largest image sharing networks and ensuring open access between networks, Intelerad takes a critical step in advancing access to digital health information.

“As an advocate for radiology’s critical role in health equity, I am so encouraged by the announcement of this expanded network and its commitment to interoperability,” said Dr. Geraldine McGinty, past President of the ACR. “Patients and physicians alike need an easy way to share images and this is an important first step toward enabling vendors to work together as they should.”

Leading healthcare systems have been pushing for seamless interoperability. “At our recent Enterprise Imaging Summit, interoperability of imaging data was a top concern expressed by many healthcare systems,” said Adam Gale, CEO of KLAS Research, the leading healthcare research firm. “As healthcare continues to evolve, the dedication to interoperability becomes critical to advancing the industry. While the future is unknown, we are hopeful this move to enhance the sharing of images will benefit all patients.”

With this transaction, Intelerad and Life Image serve many of the largest medical institutions in the world, including Mayo Clinic, Cleveland Clinic and New York Presbyterian Hospital. The combined network manages over 80 billion images globally, enabling 24/7 digital image sharing from any device wherever the provider or patient may be.

“Together we have both worked to advance patient care and are excited to have the opportunity to bring these two leading networks together to advance interoperability,” said Morris Panner, President of Intelerad and former CEO of Ambra Health, which was acquired by Intelerad in Oct 2021. “As independent companies we competed, but also pioneered some of the most important cross-vendor exchanges in the industry. By combining, we are able to advance our vision and technology more rapidly and achieve our joint vision of a true nation-wide, electronic image exchange network. We are just getting started.”

For more information regarding the acquisition of Life Image, or Intelerad’s commitment to interoperability, please visit intelerad.com and follow the company on social media at @Intelerad. AGC Partners advised on this transaction.

About Life Image

Life Image is the world’s largest medical evidence network providing access to points of care and curated clinical and imaging data. It is the only company in the market today with Real World Imaging™ that provides large-scale, heterogeneous, de-identified imaging sets for research that are linkable to other longitudinal data. Founded in 2008, Life Image has created a digital platform using industry-leading interoperability standards to connect 13,000 facilities with more than 160,000 U.S. providers and 58,000 global clinics. Its network of hospitals, physicians, patients, life sciences, medical devices, and telehealth is interconnected with a technical ecosystem of EHRs, PACS, AI solutions, cloud environments, and analytics platforms.

About Intelerad

Intelerad is one of the leading providers of medical imaging software and services for the healthcare industry. Headquartered in Raleigh, NC and Montreal, Intelerad has over 900 employees located in offices across six countries. Nearly 2,500 healthcare organizations around the world rely on Intelerad products to manage patient data, helping them reduce time and workload while improving patient outcomes. Intelerad’s award-winning enterprise imaging solutions have been recognized globally by KLAS, with Intelerad’s Ambra Health ranked #1 for Image Exchange in the 2022 Best in KLAS: Software and Professional Services report. To learn more, visit intelerad.com.

Share article on social media or email:

Prevent Blindness Names Megan Molony, SVP, Chief Merchandising and Managed Care Officer, of National Vision Inc., as the 2023 Person of Vision Award Recipient


Megan Molony, senior vice president, chief merchandising and managed care officer, of National Vision Inc., named the 2023 Person of Vision Award recipient from Prevent Blindness.

“We are thrilled to honor Megan Molony not only for her work to help the public see clearly, but also for her commitment to developing the next generation of leaders in the vision industry,” said Jeff Todd, president and CEO of Prevent Blindness.

Prevent Blindness, the nation’s leading eye health and safety nonprofit organization, announced today that the 2023 Person of Vision Award will be presented to Megan Molony, senior vice president, chief merchandising and managed care officer, of National Vision Inc. The award presentation event will take place on March 16, 2023, at 583 Park Avenue, New York, N.Y., in conjunction with Vision Expo East. All proceeds from the event help fund the vision and eye health programs of Prevent Blindness.

The Prevent Blindness Person of Vision Award recognizes an individual, corporation and/or organization whose inspired outlook champions healthy vision and its importance for a healthy life. Molony was chosen as the recipient of the Person of Vision Award for years of dedicated commitment to healthy vision, access to affordable eyecare, and industry mentorship.

Megan Molony has been a part of the optical industry for more than 25 years. She has served in various key leadership roles across several different functional areas for some of the largest global optical companies, including both Luxottica and Essilor, as well as National Vision. As National Vision’s chief merchandising and managed care officer, Molony has strategic oversight of product, pricing, visual merchandising, and managed care payor relationships/contracts. She holds a Bachelor of Science degree from Purdue University.

In addition to her role at National Vision, Molony has been very active in supporting the overall industry. She is currently a board member of the Optical Women’s Association, and the National Association of Vision Care Plans (NAVCP). She has also served to develop the vision industry’s future leaders by serving as a mentor for The Vision Council’s Emerging Optical Leaders program, and is a past board member for the global nonprofit, OneSight from the EssilorLuxottica Foundation.

National Vision is the second largest optical retail company in the United States by sales, with more than 1,300 stores in 44 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates five retail brands: America’s Best Contacts & Eyeglasses, Eyeglass World, Vision Centers inside select Walmart stores, and Vista Optical inside select Fred Meyer stores and on select military bases, as well as several e-commerce websites, offering a variety of products and services for customers’ eye care needs.

“We are thrilled to honor Megan Molony not only for her work to help the public see clearly, but also for her commitment to developing the next generation of leaders in the vision industry,” said Jeff Todd, president and CEO of Prevent Blindness. “We invite everyone to come celebrate with us at our 2023 Person of Vision event to honor Ms. Molony and help raise funds to support our sight-saving mission!”

“It is certainly an honor to be in the company of the many great visionaries that have received this award in the past,” said Ms. Molony. “I am incredibly lucky to be able to spend a career in an industry with so many visionaries, caregivers and thought leaders doing amazing work to truly improve and change lives. Many thanks to Prevent Blindness for the generous recognition.”

For more information, including sponsorship opportunities, Person of Vision Award committee membership, and reservations, please contact Sue Corbett at (312) 363-6014 or scorbett@preventblindness.org or visit https://preventblindness.org/personofvision.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Share article on social media or email: